ReviewCancer control : journal of the Moffitt Cancer Center
Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.
Review in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- DEPDC7 as a potential tumor suppressor in hepatocellular carcinoma: preliminary evidence for targeting the JAK1/STAT3 axis.Frontiers in oncology · 2026Article
- New pyrimidine derivatives as potential agents against hepatocellular carcinoma: design, synthesis, andFrontiers in pharmacology · 2026Article
- BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Simvastatin Induces Apoptosis And Suppresses Hepatocellular Carcinoma Induced In Rats.Applied biochemistry and biotechnology · 2023Article
- An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma.Life (Basel, Switzerland) · 2022Review
- An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.BMC complementary medicine and therapies · 2022Article
- Targets of immunotherapy for hepatocellular carcinoma: An update.World journal of hepatology · 2022Review
- Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook.Journal of hepatocellular carcinoma · 2022Review
- Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC.Cancers · 2021Review
- Glutathione Peroxidase 8 Suppression by Histone Deacetylase Inhibitors Enhances Endoplasmic Reticulum Stress and Cell Death by Oxidative Stress in Hepatocellular Carcinoma Cells.Antioxidants (Basel, Switzerland) · 2021Article
- Identification and analysis of immune-related subtypes of hepatocellular carcinoma.Experimental biology and medicine (Maywood, N.J.) · 2021Article
- Article
- Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.Liver research (Beijing, China) · 2020Article
- Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.World journal of gastroenterology · 2020Review
- Identification of potential hub genes associated with the pathogenesis and prognosis of hepatocellular carcinoma via integrated bioinformatics analysis.The Journal of international medical research · 2020Article
- Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.World journal of gastroenterology · 2019Review
- Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life.Cancers · 2019Review
- Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.World journal of hepatology · 2019Review
- Article
- Is This Patient's Liver Mass Cancer?Journal of the advanced practitioner in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is an aggressive tumor that often arises in the setting of liver cirrhosis. Although early-stage disease is often amenable for surgical resection, transplant, or locoregional therapies, many patients are diagnosed at an advanced stage or have poor liver reserve. Systemic therapy is the mainstay of treatment for these patients. At present, the only approved therapy for the treatment of advanced disease is the tyrosine multikinase inhibitor sorafenib. Candidacy for treatment is based on liver reserve. Novel agents for the treatment of this disease are urgently needed. In this article, we review systemic therapy trials and upcoming data for the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.